TY - JOUR
T1 - Cell-penetrating d-Isomer Peptides of p53 C-terminus
T2 - Long-term Inhibitory Effect on the Growth of Bladder Cancer
AU - Araki, Daiji
AU - Takayama, Kentaro
AU - Inoue, Miyabi
AU - Watanabe, Toyohiko
AU - Kumon, Hiromi
AU - Futaki, Shiroh
AU - Matsui, Hideki
AU - Tomizawa, Kazuhito
N1 - Funding Information:
This work was supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan and by a Grant-in-aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan . Kentaro Takayama is grateful for JSPS Research Fellowship for Young Scientists.
PY - 2010/4
Y1 - 2010/4
N2 - Objectives: To investigate whether a single application of the membrane-permeable d-isomer of the p53 C-terminus connected with a retro-inverso version of the NH2-terminal 20-amino acid peptide of the influenza virus hemagglutinin-2 protein (riHA2) inhibited the growth of bladder cancer cells. The transduction of p53 using poly-arginine is useful for targeting and suppressing the growth of bladder cancer cells. However, the protein's intracellular half-life is short, and repeated application is necessary to achieve an anti-tumor effect. Methods: The p53 carboxyl-terminal peptides covalently coupled with cell-penetrating peptides were synthesized with d- or l-amino acids. Moreover, the peptides were connected with riHA2 by a disulfide bridge. Human bladder cancer cell lines were incubated with each peptide and cell viability was assessed with the WST assay. Apoptotic cells were confirmed by Hoechst and active capase-3 staining. The p53 peptides were injected into severe combined immunodeficiency disease mice transplanted with J82 cells to investigate their anti-tumor effect on bladder tumors. A survival curve was plotted using the Kaplan-Meier method. Results: A single application of cell-penetrating d-isomer peptides of the p53 C-terminus connected with riHA2 (d11R-p53C′-riHA2 and dFHV-p53C′-riHA2) inhibited the growth and induced the apoptosis of bladder cancer cells. The tumor-bearing mice treated only with vehicle had a mean survival time of 12 days, whereas treatment with d11R-p53C′-riHA2 resulted in a long-term survival rate of 50%. Conclusions: Peptide transduction therapy using the d-isomer p53 C-terminal peptide with riHA2 may be an innovative method for the treatment of bladder cancer.
AB - Objectives: To investigate whether a single application of the membrane-permeable d-isomer of the p53 C-terminus connected with a retro-inverso version of the NH2-terminal 20-amino acid peptide of the influenza virus hemagglutinin-2 protein (riHA2) inhibited the growth of bladder cancer cells. The transduction of p53 using poly-arginine is useful for targeting and suppressing the growth of bladder cancer cells. However, the protein's intracellular half-life is short, and repeated application is necessary to achieve an anti-tumor effect. Methods: The p53 carboxyl-terminal peptides covalently coupled with cell-penetrating peptides were synthesized with d- or l-amino acids. Moreover, the peptides were connected with riHA2 by a disulfide bridge. Human bladder cancer cell lines were incubated with each peptide and cell viability was assessed with the WST assay. Apoptotic cells were confirmed by Hoechst and active capase-3 staining. The p53 peptides were injected into severe combined immunodeficiency disease mice transplanted with J82 cells to investigate their anti-tumor effect on bladder tumors. A survival curve was plotted using the Kaplan-Meier method. Results: A single application of cell-penetrating d-isomer peptides of the p53 C-terminus connected with riHA2 (d11R-p53C′-riHA2 and dFHV-p53C′-riHA2) inhibited the growth and induced the apoptosis of bladder cancer cells. The tumor-bearing mice treated only with vehicle had a mean survival time of 12 days, whereas treatment with d11R-p53C′-riHA2 resulted in a long-term survival rate of 50%. Conclusions: Peptide transduction therapy using the d-isomer p53 C-terminal peptide with riHA2 may be an innovative method for the treatment of bladder cancer.
UR - http://www.scopus.com/inward/record.url?scp=77950298119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950298119&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2009.10.002
DO - 10.1016/j.urology.2009.10.002
M3 - Article
C2 - 19963248
AN - SCOPUS:77950298119
SN - 0090-4295
VL - 75
SP - 813
EP - 819
JO - Urology
JF - Urology
IS - 4
ER -